201 related articles for article (PubMed ID: 37126184)
41. Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review.
Castillo DR; Park D; Jeon WJ; Joung B; Lee J; Yang C; Pham B; Hino C; Chong E; Shields A; Nguyen A; Brothers J; Liu Y; Zhang KK; Cao H
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373354
[TBL] [Abstract][Full Text] [Related]
42. 25-Hydroxy vitamin D deficiency predicts inferior prognosis in mantle cell lymphoma.
Xu DM; Liang JH; Wang L; Zhu HY; Xia Y; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1003-1009. PubMed ID: 31915915
[TBL] [Abstract][Full Text] [Related]
43. [Change of NK Cell Number in Peripheral Blood of Patients with Mantle Cell Lymphoma and Its Clinical Significance].
Han DL; Han YY; Bao YL; Zhao WX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):772-776. PubMed ID: 28641633
[TBL] [Abstract][Full Text] [Related]
44. Elevated SOX11 mRNA level correlates with favorable prognosis in mantle cell lymphoma.
He J; Xi Y; Gao N; Xu E; Xie L; Chang J; Liu J
J BUON; 2019; 24(4):1679-1685. PubMed ID: 31646825
[TBL] [Abstract][Full Text] [Related]
45. T-cell levels are prognostic in mantle cell lymphoma.
Nygren L; Wasik AM; Baumgartner-Wennerholm S; Jeppsson-Ahlberg Å; Klimkowska M; Andersson P; Buhrkuhl D; Christensson B; Kimby E; Wahlin BE; Sander B
Clin Cancer Res; 2014 Dec; 20(23):6096-104. PubMed ID: 25294911
[TBL] [Abstract][Full Text] [Related]
46. [Relationship of Expression of Circ_cgga162 with the Prognosis of Patients with Mantle Cell Lymphoma].
Li Y; Jia ZW; Liu JX; Ye JW; Kong XY; Yang ZF; Liu XY; Luo JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):876-880. PubMed ID: 32552951
[TBL] [Abstract][Full Text] [Related]
47. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.
Vegliante MC; Palomero J; Pérez-Galán P; Roué G; Castellano G; Navarro A; Clot G; Moros A; Suárez-Cisneros H; Beà S; Hernández L; Enjuanes A; Jares P; Villamor N; Colomer D; Martín-Subero JI; Campo E; Amador V
Blood; 2013 Mar; 121(12):2175-85. PubMed ID: 23321250
[TBL] [Abstract][Full Text] [Related]
48. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
Condoluci A; Rossi D; Zucca E; Cavalli F
Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
Ramsower CA; Rosenthal A; Robetorye RS; Mwangi R; Maurer M; Villa D; McDonnell T; Feldman A; Cohen JB; Habermann T; Campo E; Clot G; Bühler MM; Kulis M; Martin-Subero JI; Giné E; Cook JR; Hill B; Raess PW; Beiske KH; Reichart A; Hartmann S; Holte H; Scott D; Rimsza L
Br J Haematol; 2024 Jan; 204(1):160-170. PubMed ID: 37881141
[TBL] [Abstract][Full Text] [Related]
50.
Ferrero S; Rossi D; Rinaldi A; Bruscaggin A; Spina V; Eskelund CW; Evangelista A; Moia R; Kwee I; Dahl C; Di Rocco A; Stefoni V; Diop F; Favini C; Ghione P; Mahmoud AM; Schipani M; Kolstad A; Barbero D; Novero D; Paulli M; Zamò A; Jerkeman M; da Silva MG; Santoro A; Molinari A; Ferreri A; Grønbæk K; Piccin A; Cortelazzo S; Bertoni F; Ladetto M; Gaidano G
Haematologica; 2020 Jun; 105(6):1604-1612. PubMed ID: 31537689
[TBL] [Abstract][Full Text] [Related]
51. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Geisler CH; Kolstad A; Laurell A; Jerkeman M; Räty R; Andersen NS; Pedersen LB; Eriksson M; Nordström M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E;
Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180
[TBL] [Abstract][Full Text] [Related]
52. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E;
Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239
[TBL] [Abstract][Full Text] [Related]
53. CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases.
Xu J; Medeiros LJ; Saksena A; Wang M; Zhou J; Li J; Yin CC; Tang G; Wang L; Lin P; Li S
Oncotarget; 2018 Feb; 9(14):11441-11450. PubMed ID: 29545910
[TBL] [Abstract][Full Text] [Related]
54. Prognostic relevance of clinical risk factors in mantle cell lymphoma.
Hoster E
Semin Hematol; 2011 Jul; 48(3):185-8. PubMed ID: 21782060
[TBL] [Abstract][Full Text] [Related]
55. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.
Yatabe Y; Suzuki R; Tobinai K; Matsuno Y; Ichinohasama R; Okamoto M; Yamaguchi M; Tamaru J; Uike N; Hashimoto Y; Morishima Y; Suchi T; Seto M; Nakamura S
Blood; 2000 Apr; 95(7):2253-61. PubMed ID: 10733493
[TBL] [Abstract][Full Text] [Related]
56.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
57. Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma.
Miao Y; Zhou XH; Guo JJ; Sun Q; Shi K; Wu JZ; Zhu HY; Wang L; Fan L; Xu W; Li JY
Cancer Med; 2019 Jun; 8(6):2751-2758. PubMed ID: 30980510
[TBL] [Abstract][Full Text] [Related]
58. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
Hermine O; Jiang L; Walewski J; Bosly A; Thieblemont C; Szymczyk M; Pott C; Salles G; Feugier P; Hübel K; Haioun C; Casasnovas RO; Schmidt C; Bouabdallah K; Ribrag V; Kanz L; Dürig J; Metzner B; Sibon D; Cheminant M; Burroni B; Klapper W; Hiddemann W; Unterhalt M; Hoster E; Dreyling M;
J Clin Oncol; 2023 Jan; 41(3):479-484. PubMed ID: 36469833
[No Abstract] [Full Text] [Related]
59. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
Goswami RS; Atenafu EG; Xuan Y; Waldron L; Reis PP; Sun T; Datti A; Xu W; Kuruvilla J; Good DJ; Lai R; Church AJ; Lam WS; Baetz T; Lebrun DP; Sehn LH; Farinha P; Jurisica I; Bailey DJ; Gascoyne RD; Crump M; Kamel-Reid S
J Clin Oncol; 2013 Aug; 31(23):2903-11. PubMed ID: 23835716
[TBL] [Abstract][Full Text] [Related]
60. [
Vergote VKJ; Verhoef G; Janssens A; Woei-A-Jin FJSH; Laenen A; Tousseyn T; Dierickx D; Deroose CM
Leuk Lymphoma; 2023 Jan; 64(1):161-170. PubMed ID: 36223113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
